Standard BioTools Inc at UBS Genomics 2.0 and MedTech Innovations Summit Transcript
Well, good morning, everyone. Thanks for starting off day 2 here at the UBS conference. We'll start off this morning with an emerging life science technologies panels, focusing across Genomics and Proteomics. I have two CEOs from the emerging companies. We have Wenbin Jiang, who's CEO of Cytek Biosciences; and then Michael Egholm, who is President and CEO of Standard Biosciences.
Welcome, gentlemen. Thank you for joining us this morning.
Questions & Answers
Maybe to start it off, could you two give us just a briefer overview of your companies, what kind of instruments you have? And how are you positioned in the market?
Do you want to go first?
Yes. Cytek Biosciences is a company that providing cell analysis solution and the products that we have -- we actually provide a broad portfolio of flow cytometers including our full spectral flow
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |